Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11

IMPORTANCE: Sensitive outcome measures for disease progression are needed for treatment trials of Stargardt disease. OBJECTIVE: To estimate the progression rate of atrophic lesions in the prospective Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study over a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Ophthalmol
Main Authors: Strauss, Rupert W., Kong, Xiangrong, Ho, Alexander, Jha, Anamika, West, Sheila, Ip, Michael, Bernstein, Paul S., Birch, David G., Cideciyan, Artur V., Michaelides, Michel, Sahel, José-Alain, Sunness, Janet S., Traboulsi, Elias I., Zrenner, Eberhart, Pitetta, Sean, Jenkins, Dennis, Hariri, Amir Hossein, Sadda, SriniVas, Scholl, Hendrik P. N.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681653/
https://ncbi.nlm.nih.gov/pubmed/31369039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2019.2885
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados